The Novel ATM Inhibitor (AZ31) Enhances Antitumor Activity in Patient Derived Xenografts That Are Resistant to Irinotecan Monotherapy
Oncotarget - United States
doi 10.18632/oncotarget.22920
Full Text
Open PDFAbstract
Available in full text
Categories
Date
December 5, 2017
Authors
Publisher
Impact Journals, LLC